SCHEMBL1254789

SCHEMBL1254789

O=C(Nc1nc(-c2ccco2)c(C(=O)C2CCC2)s1)c1ccncc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.58
MEN1 O00255 3/20 0.58
ALDH1A1 P00352 3/20 0.58
KMT2A Q03164 3/20 0.58
KDM4E B2RXH2 2/20 0.58
MAPT P10636 2/20 0.58
PKM P14618 2/20 0.58
POLB P06746 2/20 0.58
LMNA P02545 1/20 0.58
ADORA1 P30542 9/20 0.50
ADORA2A P29274 8/20 0.50
ADORA2B P29275 6/20 0.50
ADORA3 P0DMS8 5/20 0.50
USP2 O75604 2/20 0.48
HSP90AA1 P07900 1/20 0.47
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2D6 P10635 1/20 0.45
NPC1 O15118 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1257197 0.98 L3MBTL1 (0.55) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1254481 0.97 L3MBTL1 (0.54) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1256230 0.96 L3MBTL1 (0.52) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1255719 0.92 L3MBTL1 (0.48) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1257266 0.92 L3MBTL1 (0.48) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1255418 0.91 L3MBTL1 (0.48) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1256478 0.89 L3MBTL1 (0.46) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1256269 0.86 L3MBTL1 (0.65) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1255860 0.86 L3MBTL1 (0.54) L3MBTL1MEN1ALDH1A1KMT2AKDM4E
SCHEMBL1256301 0.85 ALDH1A1 (0.75) L3MBTL1MEN1ALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 L3MBTL1 436/4885MEN1 1954/4885ALDH1A1 1344/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA L3MBTL1 702/4885MEN1 2780/4885ALDH1A1 769/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 L3MBTL1 2618/4885MEN1 3563/4885ALDH1A1 1290/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 L3MBTL1 2473/4885MEN1 3769/4885ALDH1A1 2843/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 L3MBTL1 1732/4885MEN1 4098/4885ALDH1A1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.